Hims & Hers Health, Inc.

In recent trading, shares of Hims & Hers Health Inc (Symbol: HIMS) have crossed above the average analyst 12-month target price of $15.18, changing hands for $15.51/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.
There are 12 different analyst targets within the Zacks coverage universe contributing to that average for Hims & Hers Health Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $11.00. And then on the other side of the spectrum one analyst has a target as high as $18.00. The standard deviation is $2.098.
But the whole reason to look at the average HIMS price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with HIMS crossing above that average target price of $15.18/share, investors in HIMS have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $15.18 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Hims & Hers Health Inc:
The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on HIMS — FREE.
Also see:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

HIMS Crosses Above Average Analyst Target

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Hims & Hers Health Inc (Symbol: HIMS), where a total volume of 180,627 contracts has been traded thus far today, a contract volume which is representative of approximately 18.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 63.9% of HIMS's average daily trading volume over the past month, of 28.3 million shares. Particularly high volume was seen for the $50 strike call option expiring September 19, 2025, with 9,761 contracts trading so far today, representing approximately 976,100 underlying shares of HIMS. Below is a chart showing HIMS's trailing twelve month trading history, with the $50 strike highlighted in orange:
UnitedHealth Group Inc (Symbol: UNH) saw options trading volume of 118,179 contracts, representing approximately 11.8 million underlying shares or approximately 63.7% of UNH's average daily trading volume over the past month, of 18.6 million shares. Particularly high volume was seen for the $320 strike call option expiring September 19, 2025, with 6,501 contracts trading so far today, representing approximately 650,100 underlying shares of UNH. Below is a chart showing UNH's trailing twelve month trading history, with the $320 strike highlighted in orange:
And Summit Therapeutics Inc (Symbol: SMMT) saw options trading volume of 19,339 contracts, representing approximately 1.9 million underlying shares or approximately 61.1% of SMMT's average daily trading volume over the past month, of 3.2 million shares. Particularly high volume was seen for the $31 strike call option expiring October 17, 2025, with 9,297 contracts trading so far today, representing approximately 929,700 underlying shares of SMMT. Below is a chart showing SMMT's trailing twelve month trading history, with the $31 strike highlighted in orange:
For the various different available expirations for HIMS options, UNH options, or SMMT options, visit StockOptionsChannel.com.
Also see:
Institutional Holders of SPMC
Institutional Holders of IEFC
WBA Videos
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Wednesday Option Activity: HIMS, UNH, SMMT

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.
HIMS & HERS HEALTH INC (HIMS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 68% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of HIMS & HERS HEALTH INC
More Information on Motley Fool
About Motley Fool: Brothers David and Tom Gardner often wear funny hats in public appearances, but they're hardly fools -- at least not the kind whose advice you should readily dismiss. The Gardners are the founders of the popular Motley Fool web site, which offers frank and often irreverent commentary on investing, the stock market, and personal finance. The Gardners' "Fool" really is a multi-media endeavor, offering not only its web content but also several books written by the brothers, a weekly syndicated newspaper column, and subscription newsletter services.
Additional Research Links
Dividend Aristocrats 2025
Wide Moat Stocks
High Insider Ownership Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Detailed Fundamental Analysis - HIMS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in On Holding AG (Symbol: ONON), where a total volume of 42,104 contracts has been traded thus far today, a contract volume which is representative of approximately 4.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.6% of ONON's average daily trading volume over the past month, of 8.3 million shares. Particularly high volume was seen for the $37.50 strike put option expiring November 21, 2025, with 8,258 contracts trading so far today, representing approximately 825,800 underlying shares of ONON. Below is a chart showing ONON's trailing twelve month trading history, with the $37.50 strike highlighted in orange:
Hims & Hers Health Inc (Symbol: HIMS) saw options trading volume of 172,420 contracts, representing approximately 17.2 million underlying shares or approximately 50.4% of HIMS's average daily trading volume over the past month, of 34.2 million shares. Particularly high volume was seen for the $50 strike call option expiring October 17, 2025, with 16,887 contracts trading so far today, representing approximately 1.7 million underlying shares of HIMS. Below is a chart showing HIMS's trailing twelve month trading history, with the $50 strike highlighted in orange:
And Abercrombie & Fitch Co (Symbol: ANF) saw options trading volume of 9,499 contracts, representing approximately 949,900 underlying shares or approximately 50% of ANF's average daily trading volume over the past month, of 1.9 million shares. Especially high volume was seen for the $90 strike put option expiring August 22, 2025, with 1,950 contracts trading so far today, representing approximately 195,000 underlying shares of ANF. Below is a chart showing ANF's trailing twelve month trading history, with the $90 strike highlighted in orange:
For the various different available expirations for ONON options, HIMS options, or ANF options, visit StockOptionsChannel.com.
Also see:
JNUG shares outstanding history
Institutional Holders of CXO
FOUR shares outstanding history
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: ONON, HIMS, ANF

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained future growth.
HIMS & HERS HEALTH INC (HIMS) is a mid-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of HIMS & HERS HEALTH INC
More Information on Partha Mohanram
About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Sometimes research that changes the investing world can come from the halls of academia. Partha Mohanram is a great example of this. While academic research has shown that value investing works over time, it has found the opposite for growth investing. Mohanram turned that research on its head by developing a growth model that produced significant market outperformance. His research paper "Separating Winners from Losers among Low Book-to-Market Stocks using Financial Statement Analysis" looked at the criteria that can be used to separate growth stocks that continue their upward trajectory from those that don't. Mohanram is currently the John H. Watson Chair in Value Investing at the University of Toronto and was previously an Associate Professor at the Columbia Business School.
Additional Research Links
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

HIMS Factor-Based Stock Analysis

Autonomous Vehicles Hit an Inflection Point; GPT-5 Is Here

For Immediate Release
Chicago, IL – August 14, 2025– Today, Zacks Investment Ideas feature highlights IonQ IONQ, Hims and Hers HIMS, Eli Lilly LLY and TransMedics Group TMDX.
3 Unusual Insider Transactions You Should Know About
Insider transactions, particularly insider buys, are a valuable tool for investors to monitor because they can provide insight into how the company's management team feels about the company's future. Additionally, insider buy transactions may provide peace of mind for investors, signaling that management has skin in the game and is willing to bet on themselves.
For instance, in a March 25th article, I pointed out that two IonQ insiders made unusually large purchases of IONQ stock. The insider buys were particularly attention-grabbing for a few reasons, including the larger-than-normal size of the transactions and the fact that more than one insider was buying shares. Since then, shares have risen nearly 60% and have doubled in value at one point.
Insider Trades: What to look for
Investors need to understand that when it comes to analyzing insider transactions, not all are equal. Insider buys typically hold more weight for investors because insiders only buy stock for one reason – they believe the share price will increase.
Conversely, insider sales are less meaningful because insiders may have pre-planned sales or may be selling stock for personal reasons (though there are, of course, exceptions to the rule). The two most important factors to look for are time and size. If an insider buys stock for the first time in years and buys a lot, it's usually a good omen for the stock.
3 Recent Insider Transactions to Watch
HIMS CEO Makes Largest Insider Sale in Company History
Recent filings show that Hims and Hers CEO Andrew Dudum sold more than $30 million worth of HIMS stock. Unfortunately, the insider sale is not a one-off instance. Insiders have sold a combined $199 million worth of shares during the past year!
In addition to the troubling insider sells, HIMS has been a choppy, news-driven, and difficult stock to trade.
LLY Insiders Buy the Dip
Pharma giant Eli Lilly shares suffered a 14% drop on August 7th after a worse-than-anticipated earnings report. However, a slew of LLY insiders see the dip as an opportunity to scoop up cheap shares. Since the EPS report, five insiders, including CEO David A. Ricks, bought nearly $3 million worth of stock. The large multiple buys may mean that the stock is nearing a bottom.
TMDX CEO Bets Big
The latest insider transaction filings show that TransMedics Group CEO & President Waleed Hassanein bought nearly $2 million worth of his company's stock. The transaction marks the first insider buy of the medical products company since 2023.
Bottom Line
While no single indicator can guarantee a stock's performance, the pattern of insider transactions can offer a powerful glimpse into a company's prospects.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Quantitative Momentum Investor model based on the published strategy of Wesley Gray. This momentum model looks for stocks with strong and consistent intermediate-term relative performance.
HIMS & HERS HEALTH INC (HIMS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of HIMS & HERS HEALTH INC
More Information on Wesley Gray
About Wesley Gray: Wesley Gray is the founder of Alpha Architect and the author (along with co-author Jack Vogel) of "Quantitative Momentum A Practitioner's Guide to Building a Momentum-Based Stock Selection System". He is also the author (along with co-author Tobias Carlisle) of "Quantitative Value: A Practitioner's Guide to Automating Intelligent Investment and Eliminating Behavioral Errors". He is an industry recognized expert in the application of quantitative investing strategies. Wes is also a former Marine and has his Phd from the Univerisity of Chicago, where he studied under Nobel Prize winner Eugene Fama.
Additional Research Links
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Guru Fundamental Report for HIMS

Insider Transactions Analysis Can Help with Conviction
Insider transactions, particularly insider buys, are a valuable tool for investors to monitor because they can provide insight into how the company’s management team feels about the company’s future. Additionally, insider buy transactions may provide peace of mind for investors, signaling that management has skin in the game and is willing to bet on themselves.
For instance, in a March 25th article, I pointed out that two IonQ (IONQ) insiders made unusually large purchases of IONQ stock. The insider buys were particularly attention-grabbing for a few reasons, including the larger-than-normal size of the transactions and the fact that more than one insider was buying shares. Since then, shares have risen nearly 60% and have doubled in value at one point.
Image Source: Zacks Investment Research
Insider Trades: What to look for
Investors need to understand that when it comes to analyzing insider transactions, not all are equal. Insider buys typically hold more weight for investors because insiders only buy stock for one reason – they believe the share price will increase. Conversely, insider sales are less meaningful because insiders may have pre-planned sales or may be selling stock for personal reasons (though there are, of course, exceptions to the rule). The two most important factors to look for are time and size. If an insider buys stock for the first time in years and buys a lot, it’s usually a good omen for the stock.
3 Recent Insider Transactions to Watch
HIMS CEO Makes Largest Insider Sale in Company History
Recent filings show that Hims and Hers (HIMS) CEO Andrew Dudum sold more than $30 million worth of HIMS stock. Unfortunately, the insider sale is not a one-off instance. Insiders have sold a combined $199 million worth of shares during the past year!
Image Source: Zacks Investment Research
In addition to the troubling insider sells, HIMS has been a choppy, news-driven, and difficult stock to trade.
LLY Insiders Buy the Dip
Pharma giant Eli Lilly (LLY) shares suffered a 14% drop on August 7th after a worse-than-anticipated earnings report. However, a slew of LLY insiders see the dip as an opportunity to scoop up cheap shares. Since the EPS report, five insiders, including CEO David A. Ricks, bought nearly $3 million worth of stock. The large multiple buys may mean that the stock is nearing a bottom.
Image Source: Zacks Investment Research
TMDX CEO Bets Big
The latest insider transaction filings show that TransMedics Group (TMDX) CEO & President Waleed Hassanein bought nearly $2 million worth of his company’s stock. The transaction marks the first insider buy of the medical products company since 2023.
Image Source: Zacks Investment Research
Bottom Line
While no single indicator can guarantee a stock’s performance, the pattern of insider transactions can offer a powerful glimpse into a company’s prospects.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	292.63 23.75
Price/Sales	4.87 3.01
P/B	14.02 2.20
P/FCF	52.29 18.30

Indicator	TTM Median
ROE	4.93 25.41
ROA	3.81 6.00
Net Worth	5.50 0.20
Quick Ratio	2.30 1.71
Current Ratio	2.68 2.83

Indicator	TTM Median
Net Profit Margin	1.59 10.25
Operating Margin	1.12 14.24
Gross Margin	82.12 68.59
Return on tangible equity	7.88 53.53

Indicator	TTM Median
EPS	0.06 0.37
EPS Forecast	0.06 0.37
Revenue	402.00M 16.00M
Gross Profit	318.00M —
EBITDA	13.00M —

Hims & Hers Health, Inc.

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue